NOT FOR REPRINT
Page Printed from: benefitspro.com/author/profile/kristen-v-brown
Sign In To follow
23andMe will pay $400 million for drug-delivery service Lemonaid in a bid to make its personalized genetics approach part of patients' primary care.
Verily hopes that its data-crunching and technological prowess can help employers more accurately assess what sort of risks they face.
GoodRx joins the ever-growing list of companies seeking to turn quick, convenient online doctor visits into big business.
In one instance, Medicaid recipients were offered $20 for DNA swabs and their health insurance information.
The Trump administration and Congress are gearing up for a renewed campaign to bring the companies to heel. Will it work?
The genotyping data a customer gets from 23andMe, for example, would be worth 50 shares, according to Luna.